A New Dawn for Huntington's? Skyhawk's Oral Drug Halts Disease March

BOSTON, MA – June 30, 2026 – For decades, a diagnosis of Huntington's disease (HD) has been a one-way ticket, a slow, inexorable decline of motor, cognitive, and functional abilities with no approved treatment to alter its course. Today, that grim narrative may have a new chapter. Skyhawk Therapeutics, a Boston-based biotechnology firm, has unveiled twelve-month interim data from its Phase 1/2 trial of SKY-0515, an investigational oral pill that hasn't just slowed the disease's progression in patients—it appears to have stopped it, and in some measures, even reversed it.

The data, presented at the European Academy of Neurology, sent ripples through the patient and scientific communities. For a rare, hereditary, and ultimately fatal neurodegenerative disorder affecting over 40,000 people in the U.S. and hundreds of thousands worldwide, the word 'hope' is often used sparingly. Yet, the results from Skyhawk's trial are difficult to frame in any other way. Participants taking the daily pill showed favorable trends across every key metric used to track the disease, standing in stark contrast to the expected, and typically devastating, natural progression of Huntington's.

The Innovation: A Dual-Action RNA Modifier

At the heart of this potential breakthrough is Skyhawk's proprietary SKYSTAR® platform, a sophisticated engine for discovering small molecules that can precisely modulate RNA. SKY-0515, the platform's leading candidate for HD, is not just another drug; it represents a new strategic approach to tackling the disease at its genetic roots. It is an orally administered RNA splicing modifier designed to execute a two-pronged attack on the pathology of Huntington's.

First, it targets the primary culprit: the mutant huntingtin (mHTT) protein. This toxic protein, produced by a faulty gene, accumulates in the brain, leading to the death of neurons. SKY-0515 has been shown to reduce mHTT levels in the blood by up to 69% in a dose-dependent manner. This huntingtin-lowering strategy has long been the holy grail for HD researchers.

But Skyhawk's therapy goes a step further. It also reduces the expression of PMS1, a gene that has recently been identified as a key driver of disease progression. The PMS1 gene is involved in a process called somatic CAG repeat expansion, where the genetic stutter that causes HD becomes worse over time in a patient's cells, accelerating their decline. By reducing PMS1 mRNA by up to 26%, SKY-0515 may be able to pump the brakes on the disease's underlying engine. This dual mechanism—hitting both the toxic protein and the accelerator of genetic instability—is a novel and powerful strategy that sets it apart in a crowded field of research.

"We are pleased to share this exciting subcomponent data," said Sergey Paushkin, Head of R&D at Skyhawk Therapeutics, in a statement. He emphasized the potential for the drug's effect on these critical biomarkers "to offer Huntington's patients a type of therapy they have long deserved, in a convenient daily pill."

Beyond Biomarkers: Reclaiming Function and Hope

While reducing protein biomarkers is a crucial scientific victory, for patients and their families, the real measure of success is quality of life. This is where the Skyhawk data becomes truly compelling. The trial measured patient outcomes using the composite Unified Huntington's Disease Rating Scale (cUHDRS), which assesses four key areas.

In every single one, participants on SKY-0515 defied expectations. On Total Functional Capacity (TFC), which measures the ability to manage finances, work, and daily life, patients showed a slight improvement (+0.07), whereas they were expected to decline by -0.87 points. On the Total Motor Score (TMS), which assesses involuntary movements and motor impairment, patients improved by -2.00 points, a remarkable reversal compared to an expected worsening of 2.21 points. Cognitive tests measuring processing speed (SDMT) and attention (SWRT) showed similar patterns of stabilization and improvement against a backdrop of expected decline.

Perhaps most powerfully, the trial captured the subjective experience of living with the disease. In surveys, not a single patient or clinician reported a worsening of the disease over twelve months. This is unheard of for Huntington's. Furthermore, 65% of participants and 50% of their doctors assessed that there had been an improvement. In a world where stabilization would be a monumental win, improvement feels like a paradigm shift.

Navigating the Gauntlet of Drug Development

As promising as these results are, it is critical to view them with the nuanced perspective that a long history of drug development demands. These are interim results from an early-stage Phase 1/2 trial. The most striking data comes from the trial's twelve-month extension period, in which all participants, including those previously on placebo, received the active drug. While this provides valuable long-term data, the lack of a concurrent placebo group during this phase makes it harder to definitively attribute all gains to the drug alone. Researchers use sophisticated statistical comparisons to natural history datasets, like the Enroll-HD study, to provide context, but this is not a substitute for a randomized, placebo-controlled result.

This is precisely why Skyhawk is already well underway with its pivotal Phase 2/3 program, FALCON-HD. These larger, more rigorous studies, which are actively enrolling hundreds of patients worldwide, are designed to provide the definitive proof of efficacy and safety that regulatory bodies like the FDA require for approval. They are the final, and highest, hurdle to clear.

A Crowded and Hopeful Race

The path to an approved HD therapy is littered with high-profile setbacks, most notably the halting of Roche's Tominersen trial, which served as a sobering reminder of the complexities of neurodegeneration. Yet, the field is more vibrant and hopeful than ever. SKY-0515 does not exist in a vacuum. It is a leading contender in a competitive race. PTC Therapeutics' oral drug, PTC518, has also shown promising data in reducing mHTT and slowing motor symptoms. Other companies are pursuing different angles, from allele-selective gene silencing (Wave Life Sciences) to one-time gene therapies (uniQure).

What makes Skyhawk's position so compelling is its unique combination of advantages: the convenience of an oral pill, a sophisticated dual-action mechanism that targets both the toxic protein and disease acceleration, and now, a remarkable set of interim data showing not just stabilization, but tangible improvements in function, motor skills, and cognition. The journey is far from over, and the results of the pivotal FALCON-HD trials will be the ultimate arbiter. But for the first time in a long time, the Huntington's community has a clear, scientifically robust, and profoundly hopeful reason to watch the horizon.